Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · September 21, 2023

Dabrafenib Plus Trametinib for Relapsed/Refractory BRAF V600–Mutant Pediatric High-Grade Glioma

Journal of Clinical Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600-Mutant Pediatric High-Grade Glioma
J. Clin. Oncol 2023 Aug 29;[EPub Ahead of Print], DR Hargrave, K Terashima, J Hara, UR Kordes, SA Upadhyaya, F Sahm, E Bouffet, RJ Packer, O Witt, L Sandalic, A Kieloch, M Russo, KJ Cohen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Brain Cancer Center of Excellence

Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.

Further Reading